CGRP Inhibitors Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2030

Description

Persistence Market Research has recently published an in-depth analysis of the global of the CGRP inhibitors market, providing an insightful overview of the market's dynamics, growth drivers, challenges, and emerging trends. This report presenting exclusive data and statistics that forecast the market's growth trajectory from 2023 to 2030.

The global CGRP inhibitors market is forecast to expand at a CAGR of 12.0% and thereby increase from a value of US$300.0 Mn in 2023, to US$663.2 Mn by the end of 2030.

Key Insights:

CGRP Inhibitors Market Size (2023E): US$300.0 Million
Projected Market Value (2030F): US$663.2 Million
Global Market Growth Rate (CAGR 2023 to 2030): 12%
Historical Market Growth Rate (CAGR 2018 to 2022): 14%

CGRP Inhibitors Market - Report Scope:

The CGRP inhibitors market encompasses pharmaceutical products designed to inhibit the calcitonin gene-related peptide (CGRP) pathway, primarily for the treatment of migraine headaches. These inhibitors offer promising therapeutic options for patients suffering from migraines by targeting specific neurochemical pathways. Market growth is primarily driven by the increasing prevalence of migraine disorders globally, coupled with the growing adoption of novel therapeutic interventions for migraine management.

Market Growth Drivers:

The CGRP inhibitors market is fueled by the rising incidence of migraine disorders, which significantly impact the quality of life for affected individuals. As awareness regarding migraine management and treatment options increases, there is a growing demand for effective pharmaceutical interventions such as CGRP inhibitors. Additionally, advancements in drug delivery technologies and formulation strategies enhance the efficacy and tolerability of CGRP inhibitors, further driving market growth.

Market Restraints:

Despite the promising outlook, the CGRP inhibitors market faces challenges such as regulatory hurdles, reimbursement issues, and the presence of alternative treatment modalities for migraine management. Regulatory agencies impose stringent requirements for the approval of CGRP inhibitor drugs, leading to prolonged development timelines and increased costs for market players. Moreover, reimbursement policies and insurance coverage for CGRP inhibitors vary across regions, posing barriers to market penetration and adoption.

Market Opportunities:

The CGRP inhibitors market presents lucrative opportunities driven by ongoing research and development initiatives aimed at expanding the therapeutic indications of CGRP inhibitor drugs beyond migraine treatment. Additionally, the introduction of novel CGRP inhibitor formulations, such as long-acting injectables and oral tablets, offers convenience and compliance advantages to patients. Collaborations between pharmaceutical companies and research institutions further accelerate innovation in the CGRP inhibitors market, unlocking new avenues for market growth.

Key Questions Answered in the Report:

What are the key factors driving the growth of the CGRP inhibitors market?
How is the regulatory landscape influencing market dynamics and product development?
What are the emerging trends and opportunities in the global CGRP inhibitors market?
Who are the leading players in the CGRP inhibitors market, and what strategies are they adopting to gain a competitive edge?
What are the future prospects and market outlook for CGRP inhibitor drugs?

Competitive Intelligence and Business Strategy:

Leading players in the CGRP inhibitors market, including pharmaceutical companies such as Amgen, Novartis, Teva Pharmaceutical Industries Ltd., Eli Lilly, Lundbeck, Abbvie, and Allergan, focus on strategic collaborations, acquisitions, and product innovation to strengthen their market presence. These companies invest significantly in clinical research and development to expand their product portfolios and address unmet needs in migraine treatment. Furthermore, partnerships with healthcare providers and patient advocacy groups facilitate market access and promote awareness about CGRP inhibitor therapies.

Key Companies Profiled:

Amgen
Novartis
Teva Pharmaceutical Industries Ltd.
Eli Lilly
Lundbeck
Abbvie
Allergan

CGRP Inhibitors Market Research Segmentation:

The CGRP inhibitors market is segmented based on product type, indication, distribution channel, and region, providing a comprehensive analysis of market trends and opportunities across different segments.

By Molecule:

Small Molecule
Large Molecule

By Treatment:

Preventive Migraine Treatment
Acute Migraine Treatment

By Route of Administration:

Oral
Nasal
Injectables

By End-use:

Hospitals
Specialty Clinics
Mail Order Pharmacies
Retail Pharmacies

By Region:

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33710

1. Executive Summary

1.1. Global CGRP Inhibitors Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Molecule Lifecycle Analysis
2.4. CGRP Inhibitors Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Applications
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global CGRP Inhibitors Market Outlook: Molecule
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Molecule, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
  - 3.3.3.1. Small Molecule
  - 3.3.3.2. Large Molecule
3.4. Market Attractiveness Analysis: Molecule
3.5. Global CGRP Inhibitors Market Outlook: Treatment
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Treatment, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
  - 3.5.3.1. Preventive Migraine Treatment
  - 3.5.3.2. Acute Migraine Treatment
3.6. Market Attractiveness Analysis: Treatment
3.7. Global CGRP Inhibitors Market Outlook: Route of Administration
- 3.7.1. Introduction / Key Findings
- 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Route of Administration, 2018 - 2022
- 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
  - 3.7.3.1. Oral
  - 3.7.3.2. Nasal
  - 3.7.3.3. Injectables
3.8. Market Attractiveness Analysis: Route of Administration
3.9. Global CGRP Inhibitors Market Outlook: End User
- 3.9.1. Introduction / Key Findings
- 3.9.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By End User, 2018 - 2022
- 3.9.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
  - 3.9.3.1. Hospitals
  - 3.9.3.2. Specialty clinics
  - 3.9.3.3. Mail order pharmacies
  - 3.9.3.4. Retail Pharmacies
3.10. Market Attractiveness Analysis: End User

4. Global CGRP Inhibitors Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia & Pacific
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Molecule
- 5.3.3. By Treatment
- 5.3.4. By Route of Administration
- 5.3.5. By End User
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 5.5.1. Small Molecule
- 5.5.2. Large Molecule
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 5.6.1. Preventive Migraine Treatment
- 5.6.2. Acute Migraine Treatment
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 5.7.1. Oral
- 5.7.2. Nasal
- 5.7.3. Injectables
5.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 5.8.1. Hospitals
- 5.8.2. Specialty clinics
- 5.8.3. Mail order pharmacies
- 5.8.4. Retail Pharmacies
5.9. Market Attractiveness Analysis

6. Europe CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Molecule
- 6.3.3. By Treatment
- 6.3.4. By Route of Administration
- 6.3.5. By End User
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkey
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 6.5.1. Small Molecule
- 6.5.2. Large Molecule
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 6.6.1. Preventive Migraine Treatment
- 6.6.2. Acute Migraine Treatment
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 6.7.1. Oral
- 6.7.2. Nasal
- 6.7.3. Injectables
6.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 6.8.1. Hospitals
- 6.8.2. Specialty clinics
- 6.8.3. Mail order pharmacies
- 6.8.4. Retail Pharmacies
6.9. Market Attractiveness Analysis

7. East Asia CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Molecule
- 7.3.3. By Treatment
- 7.3.4. By Route of Administration
- 7.3.5. By End User
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 7.5.1. Small Molecule
- 7.5.2. Large Molecule
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 7.6.1. Preventive Migraine Treatment
- 7.6.2. Acute Migraine Treatment
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 7.7.1. Oral
- 7.7.2. Nasal
- 7.7.3. Injectables
7.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 7.8.1. Hospitals
- 7.8.2. Specialty clinics
- 7.8.3. Mail order pharmacies
- 7.8.4. Retail Pharmacies
7.9. Market Attractiveness Analysis

8. South Asia & Oceania CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Molecule
- 8.3.3. By Treatment
- 8.3.4. By Route of Administration
- 8.3.5. By End User
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 8.5.1. Small Molecule
- 8.5.2. Large Molecule
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 8.6.1. Preventive Migraine Treatment
- 8.6.2. Acute Migraine Treatment
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 8.7.1. Oral
- 8.7.2. Nasal
- 8.7.3. Injectables
8.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 8.8.1. Hospitals
- 8.8.2. Specialty clinics
- 8.8.3. Mail order pharmacies
- 8.8.4. Retail Pharmacies
8.9. Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Molecule
- 9.3.3. By Treatment
- 9.3.4. By Route of Administration
- 9.3.5. By End User
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 9.5.1. Small Molecule
- 9.5.2. Large Molecule
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 9.6.1. Preventive Migraine Treatment
- 9.6.2. Acute Migraine Treatment
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 9.7.1. Oral
- 9.7.2. Nasal
- 9.7.3. Injectables
9.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 9.8.1. Hospitals
- 9.8.2. Specialty clinics
- 9.8.3. Mail order pharmacies
- 9.8.4. Retail Pharmacies
9.9. Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Molecule
- 10.3.3. By Treatment
- 10.3.4. By Route of Administration
- 10.3.5. By End User
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Molecule, 2023 - 2030
- 10.5.1. Small Molecule
- 10.5.2. Large Molecule
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Treatment, 2023 - 2030
- 10.6.1. Preventive Migraine Treatment
- 10.6.2. Acute Migraine Treatment
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Route of Administration, 2023 - 2030
- 10.7.1. Oral
- 10.7.2. Nasal
- 10.7.3. Injectables
10.8. Current Market Size (US$ Mn) and Volume (Units) Forecast By End User, 2023 - 2030
- 10.8.1. Hospitals
- 10.8.2. Specialty clinics
- 10.8.3. Mail order pharmacies
- 10.8.4. Retail Pharmacies
10.9. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Large Molecule
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Amgen
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Novartis
- 11.3.3. Teva Pharmaceutical Industries Ltd.
- 11.3.4. Eli Lilly
- 11.3.5. Lundbeck
- 11.3.6. Abbvie
- 11.3.7. Allergan

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations